Skip to main content

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Recruiting · Phase 1 · NCT07290036

Conditions: Psoriatic Arthritis, Axial Spondyloarthritis

At a glance

Research payments reported, 2025
$36,115
U.S. investigators named
7
Sites paid
8
Planned or actual enrollment
392

About the trial

Sponsor
UCB Biopharma SRL
Tested
Bimekizumab regimen 1 iv (drug), Bimekizumab regimen 2 iv (drug), Bimekizumab regimen 3 sc (drug)
Dates
Started 2025-12-10; completion 2028-09-14
Results posted
Not yet

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

From ClinicalTrials.gov, last updated 2026-11-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

UCB SA reported $36,115 in research payments for this study in 2025 (8 payments).

Products named: Bimzelx

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Amicus Arthritis and Osteoporosis Center, Inc $11,997
  • Covina Arthritis Clinic $11,952
  • Medvin Clinical Research $11,952
  • Qps Miami Research Associates $112
  • Sunvalley Arthritis Center, Ltd $25
  • West Tennessee Research Institute - Clinical Research $25
  • Carewell Arthritis Center $25
  • Altoona Center for Clinical Research - Research $25

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.